Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGD-6972 MAD Study in Healthy and T2DM Subjects
NCT02250222Phase 1Completed
- Sponsor
- Ligand Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LGD-6972 in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Ligand Pharmaceuticals. Primary endpoint: Number of participants with one or more drug related adverse events or serious adverse events at 14 days. Started Oct 2014; status: completed.
02
Drugs
LGD-6972
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02250222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250222.